Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,583.39
(
-0.62%
)
US TECH 100
23,616.80
(
-0.75%
)
Dow Jones
45,875.49
(
-0.76%
)
Brent Oil
107.61
(
0.96%
)
Bitcoin
69,258.15
(
-2.78%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: JohnWayne post# 207850

Friday, 10/27/2017 4:46:34 PM

Friday, October 27, 2017 4:46:34 PM

Post# of 257259
MRK withdraws EU application for Keytruda/chemo in first-line NSCLC:

http://www.mrknewsroom.com/news-release/corporate-news/merck-provides-update-european-application-keytruda-pembrolizumab-combin

MRK is -3% in AH trading and was -6% during regular trading—a cumulative loss of 10% relative to yesterday’s close, making today MRK's worst day since Vioxx.

Perhaps the EMA news leaked. Requesting withdrawal of an application is the polite way in which the EMA rejects an application.

MRK received FDA accelerated approval in this indication in May 2017 (#msg-131249474).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now